A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
Clinical Trial Grant
Awarded By
Merck Sharp & Dohme
Start Date
April 2, 2021
End Date
October 7, 2024
Awarded By
Merck Sharp & Dohme
Start Date
April 2, 2021
End Date
October 7, 2024